Glucose Monitoring Specialist Dexcom has announced that it has received FDA clearance for the G7 15-day continuous glucose monitoring (CGM) system for ages 18 and above, type 2, type 2 and gestational diabetes.
The G7 15th is scheduled to be released later this year and will have a wear time of 15.5 days (According to the company, it includes a bounty period of 12 hours) and the final 15% longer than the Dexcom G7.
The new system sends real-time glucose information, every five minutes, via sensors, every five minutes without the need for fingertips or scans.
The system has a whole Mean absolute relative difference (MARD) of 8.0%. According to the NIH National Library of Medicine, Murdo is Parameters used for characterization Measurement performance of CGM systems.
The Dexcom G7 is waterproof, hands-free, Connect the sensor directly to your Apple Watch.
It also has an automated activity logging feature that allows end users to enter diet and medication information.
The Dexcom Clarity mobile app is compatible with your smartphone or computer and provides a means of sharing glucose patterns and statistics, as well as glucose data with caregivers and family members.
Meanwhile, the company is working with its insulin pump partners to ensure that the Dexcom G7 15 days are compatible with automated insulin delivery systems.
“The Dexcom G7 15th approval represents another major innovation for Dexcom,” Jake Leach, executive vice president and chief operating officer of Dexcom, said in a statement.
“We are proud to provide the most long-term wearable and most accurate CGM by listening to the needs of our users, giving people the knowledge to better control over diabetes with best-in-class technology.
Bigger trends
March, psychological metabolism digital diagnosis company Nanowear has announced a license and data partnership with Dexcom to integrate Dexcom G7 glucose data into SimpleSense nanotechnology-enabled wearables.
Nanowear offers a home-based, AI-enabled digital diagnosis for psychometabolic health. The company’s FDA-cleared SimpleSense wearable reads patient vitals including breathing rate, heart rate, blood pressure, physical activity and lung volume.
In 2024, Dexcom won $75 million We have established a strategic partnership that enables a strategic investment in ouraa, a health tracking ring manufacturer, and a two-way data flow between Dexcom’s CGM and Oura Ring.
Dexcom donated $75 million to Oura Series D funding round, bringing Oura to a valuation of over $5 billion.
via Partnership, users of both companies’ products gained access to glucose data from Dexcom’s glucose biosensors and sleep, heart health, stress, vital signs and activity data.
That same year, Dexcom expanded it It provided diabetes management capabilities and a direct connection to the Apple Watch of the G7 CGM system via a dedicated Bluetooth connection.
This feature allows users to check their glucose readings in real time without having to get an iPhone.
2022, The Dexcom G7 CGM was cleared by the FDA. The model was aimed at individuals over two years of age with all sorts of diabetes.
Other companies in the CGM space include Abbott announced in 2024 that CGM system Lingo can be purchased in the US without a prescription.
Lingo includes biosensors and mobile apps based on Abbott’s Freestyle Libre continuous glucose monitoring technology. This system is a bioaccumulation product aimed at people over the age of 18 who are not taking insulin.
The system provides personal insights and coaching to end users with the aim of tracking glucose in real time, building healthy habits, retraining metabolism and improving overall health.
That same year, Medtronic received the FDA clearance of Simplera CGM, the company’s first disposable all-in-one CGM, half the size of the previous Medtronic CGM.
The Simplera platform features the company’s CGM form factor and includes a Simplera CGM designed to be used as part of a smart MDI system with InPen smart insulin pen and a Simplera Sync sensor designed to be integrated with the minimum 780G insulin system.
Last year, Medtronic We issued voluntary recalls of minimal 600 and 700 series insulin pumps, as pumps could shorten battery life.
The company notified customers that they should track battery status and monitor minimal pump built-in alarms and alerts to track battery status and contact the company if they notice changes to the pump’s battery life.
